Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999–2010

Authors

  • S. F. Schillie,

    1. Division of Viral Hepatitis, Vaccine Research and Policy Team, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA
    Search for more papers by this author
  • J. Xing,

    1. Division of Viral Hepatitis, Epidemiology and Surveillance Branch, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author
  • T. V. Murphy,

    1. Division of Viral Hepatitis, Vaccine Research and Policy Team, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA
    Search for more papers by this author
  • D. J. Hu

    1. Division of Viral Hepatitis, Epidemiology and Surveillance Branch, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA
    Search for more papers by this author

  • The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Sarah Schillie, MD, MPH, MBA, Division of Viral Hepatitis, Vaccine Research and Policy Team, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS G-37, Atlanta, GA 30333, USA. E-mail: sschillie@cdc.gov

Abstract

Summary.  The prevalence of hepatitis B virus (HBV) infection among persons with diabetes has not been assessed among the US population, despite increasing reports of HBV transmission in institutional care settings. Using national survey data, we found a 60% higher prevalence of HBV infection among persons with (vs without) diagnosed diabetes.

Ancillary